Nearly half of Smith & Nephew investors revolt against CEO pay rise

Medical device manufacturer’s policy ultimately passed, making maximum payout for Deepak Nath $11.8m

Related Keywords

United Kingdom ,Texas ,United States ,Luke Hildyard ,Pascal Soriot ,Deepak Nath ,Rupert Soames ,Institutional Shareholder Services ,Astrazeneca ,High Pay Centre ,United Kingdom Listed ,Glass Lewis ,